Eleva Capital’s Boston Scientific BSX Stock Holding History

Eleva Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Hold	26,667	–	–	0.49%	12
2026 Q1	$1.67M	Buy	+26,667	New	+$2.13M	0.49%	12

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Eleva Capital's BSX Position: Q2 2026 in Review

Eleva Capital held its Boston Scientific (BSX) position steady in Q2 2026 at 26,667 shares worth $1.67M. The position accounts for 0.49% of the portfolio, ranked #12.

Eleva Capital first reported a position in BSX in Q1 2026 and has held it in 2 quarters since. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Eleva Capital held 26,667 shares of Boston Scientific worth $1.67M as of Q2 2026.
Eleva Capital left its Boston Scientific share count unchanged in Q2 2026.
Boston Scientific made up 0.49% of Eleva Capital's portfolio in Q2 2026, its #12 holding.
Eleva Capital first reported a position in Boston Scientific in Q1 2026 and has held it in 2 quarters since.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.